Positive Preclinical Data for Docetaxel ChemoSeed

Summary by AI BETAClose X

CRISM Therapeutics Corporation announced positive preclinical data for its Docetaxel-ChemoSeed technology in a prostate cancer model, demonstrating significant anti-tumour activity and a favourable tolerability profile compared to standard systemic docetaxel. The study showed a 58% reduction in tumour volume at its most effective dose level, with a clear dose-response relationship and no adverse tolerability effects observed in ChemoSeed-treated groups, unlike the standard of care. These results support the company's strategy of localised chemotherapy delivery and bolster confidence in the technology's potential for clinical evaluation.

Disclaimer*

UK 100

Latest directors dealings